GLP‑1 Clinical Trial Eye Safety: Semaglutide Eye Risks

GLP-1 receptor agonists, notably semaglutide, have emerged as transformative therapies for type 2 diabetes, weight management, and cardiovascular health. While celebrated for substantial weight loss and enhanced health outcomes, emerging evidence raises concerns about serious ocular complications associated with their use.

Research indicates that semaglutide users experience a fourfold increase in the risk of nonarteritic anterior ischemic optic neuropathy (NAION) and more than double the risk of developing neovascular age-related macular degeneration (nAMD), particularly among diabetic patients. Global pharmacovigilance data corroborates these alarming trends, underscoring the need for heightened awareness among healthcare providers and patients alike.

The American Optometric Association emphasizes the necessity of comprehensive eye assessments and patient education regarding the vision-related side effects of GLP-1 medications. While GLP-1 receptor agonists offer significant health benefits, proactive eye care and vigilance are essential to mitigate the risk of irreversible ocular conditions, warranting immediate action from healthcare providers, patients, and clinical research organizations to safeguard vision health.